JP2015214582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015214582A5 JP2015214582A5 JP2015160099A JP2015160099A JP2015214582A5 JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5 JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- antibody
- treatment
- her2 antibody
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017330 | 2006-08-21 | ||
| EP06017330.9 | 2006-08-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013103182A Division JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015214582A JP2015214582A (ja) | 2015-12-03 |
| JP2015214582A5 true JP2015214582A5 (https=) | 2017-08-31 |
Family
ID=37607207
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2015160099A Ceased JP2015214582A (ja) | 2006-08-21 | 2015-08-14 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20080050385A1 (https=) |
| EP (2) | EP2056874B1 (https=) |
| JP (3) | JP2010501498A (https=) |
| KR (1) | KR101136763B1 (https=) |
| CN (1) | CN101505792B (https=) |
| AR (1) | AR062419A1 (https=) |
| AU (1) | AU2007287794B2 (https=) |
| BR (1) | BRPI0715829A2 (https=) |
| CA (1) | CA2660681A1 (https=) |
| CL (1) | CL2007002404A1 (https=) |
| CO (1) | CO6150193A2 (https=) |
| CR (1) | CR10590A (https=) |
| DK (1) | DK2056874T3 (https=) |
| ES (2) | ES2546066T3 (https=) |
| IL (2) | IL196810A0 (https=) |
| MA (1) | MA30654B1 (https=) |
| MX (1) | MX2009001715A (https=) |
| MY (1) | MY150756A (https=) |
| NO (1) | NO20090450L (https=) |
| NZ (1) | NZ574580A (https=) |
| PE (1) | PE20080911A1 (https=) |
| PL (1) | PL2056874T3 (https=) |
| RU (1) | RU2528884C2 (https=) |
| SG (1) | SG174090A1 (https=) |
| SI (1) | SI2056874T1 (https=) |
| TW (2) | TW201107346A (https=) |
| WO (1) | WO2008022746A1 (https=) |
| ZA (1) | ZA200901200B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407556C (en) * | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| DK1771482T3 (da) * | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| CL2007002404A1 (es) * | 2006-08-21 | 2008-04-18 | Hoffmann La Roche | Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2. |
| SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| SG187012A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| AU2011290672B2 (en) * | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| IL301603A (en) | 2011-10-14 | 2023-05-01 | Genentech Inc | Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient |
| AR089067A1 (es) * | 2011-12-05 | 2014-07-30 | Hoffmann La Roche | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |
| US20150147340A1 (en) * | 2012-03-30 | 2015-05-28 | Fibrogen, Inc. | Therapeutic methods for peritoneal carcinomatosis |
| MX368259B (es) | 2013-04-16 | 2019-09-25 | Genentech Inc | Variantes de pertuzumab y su evaluacion. |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| TWI734775B (zh) | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
| EP3562844A1 (en) | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| TW202508629A (zh) | 2017-01-17 | 2025-03-01 | 美商建南德克公司 | 皮下her2抗體調配物 |
| PT3589661T (pt) | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| EP4208167A4 (en) * | 2020-09-04 | 2024-11-13 | The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Combination compositions and methods for treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
| WO1997049700A1 (en) | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| KR20060079258A (ko) | 1996-10-18 | 2006-07-05 | 제넨테크, 인크. | 항-ＥｒｂＢ２ 항체 |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| PT971959E (pt) | 1997-04-07 | 2006-05-31 | Genentech Inc | Anticorpos humanizados e metodos para formar anticorpos humanizados |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| KR20010071271A (ko) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법 |
| ES2237125T3 (es) | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
| ID27562A (id) | 1998-08-27 | 2001-04-12 | Pfizer Prod Inc | Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| WO2000035956A1 (fr) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
| PL349839A1 (en) | 1999-02-11 | 2002-09-23 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| DE60040981D1 (de) | 1999-05-14 | 2009-01-15 | Genentech Inc | BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| ES2282120T3 (es) | 1999-06-25 | 2007-10-16 | Genentech, Inc. | Tratamiento del cancer de prostata con anticuerpos anti-erbb2. |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PT1106612E (pt) | 1999-11-30 | 2004-06-30 | Pfizer Prod Inc | Derivados de quinolina uteis para inibir a farnesil-proteina-transferase |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| CA2466279A1 (en) * | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2003077841A2 (en) | 2002-03-12 | 2003-09-25 | The General Hospital Corporation | Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| EP2289942B1 (en) | 2002-04-10 | 2013-07-31 | Genentech, Inc. | Anti-HER2 antibody variants |
| US20040243207A1 (en) | 2003-05-30 | 2004-12-02 | Olson Donald R. | Medical implant systems |
| UA101945C2 (uk) | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| AU2004261980A1 (en) | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody CDR polypeptide sequences with restricted diversity |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| WO2006028936A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US20060147451A1 (en) * | 2004-10-04 | 2006-07-06 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
| CA2611861C (en) * | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| CL2007002404A1 (es) * | 2006-08-21 | 2008-04-18 | Hoffmann La Roche | Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2. |
| JP2013103182A (ja) * | 2011-11-15 | 2013-05-30 | Toray Ind Inc | スパイラル型流体分離素子およびその製造方法 |
-
2007
- 2007-08-17 CL CL200702404A patent/CL2007002404A1/es unknown
- 2007-08-17 DK DK07786693.7T patent/DK2056874T3/da active
- 2007-08-17 WO PCT/EP2007/007276 patent/WO2008022746A1/en not_active Ceased
- 2007-08-17 MX MX2009001715A patent/MX2009001715A/es active IP Right Grant
- 2007-08-17 AU AU2007287794A patent/AU2007287794B2/en not_active Ceased
- 2007-08-17 ES ES11193793.4T patent/ES2546066T3/es active Active
- 2007-08-17 NZ NZ574580A patent/NZ574580A/en not_active IP Right Cessation
- 2007-08-17 JP JP2009524943A patent/JP2010501498A/ja active Pending
- 2007-08-17 ES ES07786693T patent/ES2392630T3/es active Active
- 2007-08-17 KR KR1020097003557A patent/KR101136763B1/ko not_active Expired - Fee Related
- 2007-08-17 MY MYPI20090667 patent/MY150756A/en unknown
- 2007-08-17 PL PL07786693T patent/PL2056874T3/pl unknown
- 2007-08-17 EP EP07786693A patent/EP2056874B1/en not_active Revoked
- 2007-08-17 AR ARP070103667A patent/AR062419A1/es unknown
- 2007-08-17 CA CA002660681A patent/CA2660681A1/en not_active Abandoned
- 2007-08-17 EP EP11193793.4A patent/EP2441472B1/en not_active Revoked
- 2007-08-17 CN CN2007800308557A patent/CN101505792B/zh not_active Expired - Fee Related
- 2007-08-17 SI SI200731075T patent/SI2056874T1/sl unknown
- 2007-08-17 US US11/840,279 patent/US20080050385A1/en not_active Abandoned
- 2007-08-17 RU RU2009110102/15A patent/RU2528884C2/ru not_active IP Right Cessation
- 2007-08-17 BR BRPI0715829-7A2A patent/BRPI0715829A2/pt not_active Application Discontinuation
- 2007-08-17 SG SG2011060142A patent/SG174090A1/en unknown
- 2007-08-20 TW TW099141756A patent/TW201107346A/zh unknown
- 2007-08-20 PE PE2007001129A patent/PE20080911A1/es not_active Application Discontinuation
- 2007-08-20 TW TW096130765A patent/TW200825106A/zh unknown
-
2009
- 2009-01-29 IL IL196810A patent/IL196810A0/en unknown
- 2009-01-29 NO NO20090450A patent/NO20090450L/no not_active Application Discontinuation
- 2009-01-29 CR CR10590A patent/CR10590A/es not_active Application Discontinuation
- 2009-02-19 MA MA31650A patent/MA30654B1/fr unknown
- 2009-02-19 ZA ZA2009/01200A patent/ZA200901200B/en unknown
- 2009-02-24 CO CO09018558A patent/CO6150193A2/es unknown
-
2010
- 2010-05-20 US US12/784,309 patent/US20100285010A1/en not_active Abandoned
-
2011
- 2011-05-19 US US13/111,784 patent/US20110223159A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/585,095 patent/US20130183292A1/en not_active Abandoned
-
2013
- 2013-05-15 JP JP2013103182A patent/JP2013163687A/ja not_active Withdrawn
-
2015
- 2015-03-30 IL IL238045A patent/IL238045A0/en unknown
- 2015-05-13 US US14/711,671 patent/US20150239969A1/en not_active Abandoned
- 2015-08-14 JP JP2015160099A patent/JP2015214582A/ja not_active Ceased
-
2017
- 2017-10-23 US US15/791,285 patent/US20180251536A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015214582A5 (https=) | ||
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| WO2018136412A3 (en) | Subcutaneous her2 antibody formulations | |
| MY208022A (en) | Anti-claudin 18.2 antibody and application thereof | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| JP2014509659A5 (https=) | ||
| MY205774A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| JP2019506403A5 (https=) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2014512354A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| NZ719784A (en) | Specific anti-cd38 antibodies for treating human cancers | |
| MY183712A (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases | |
| JP2016515124A5 (https=) | ||
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. |